熱門資訊> 正文

Tempus更新Tempus Pixel设备获得美国FDA批准

2025-09-11 22:53

Tempus AI (NASDAQ:TEM) said that it has received clearance from the U.S. FDA for its updated Tempus Pixel, an AI-powered cardiac imaging platform.
This update allows the generation of T1 and T2 inline maps, helping the device’s capabilities for cardiac MR image analysis.

More on Tempus AI

Tempus AI, Inc. (TEM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
After An Odd Start, Tempus AI Is Making A Beeline To The Good End Of The AI Rainbow
Tempus AI: Evolving To Data Infrastructure And Monetization Options Platform
Tempus AI announces $81.25M acquisition of Paige
Tempus AI raises 2025 revenue guidance to $1.26B with 89.6% Q2 growth driven by genomics and data deals

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。